CN1306956C - 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物 - Google Patents

诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物 Download PDF

Info

Publication number
CN1306956C
CN1306956C CNB028081668A CN02808166A CN1306956C CN 1306956 C CN1306956 C CN 1306956C CN B028081668 A CNB028081668 A CN B028081668A CN 02808166 A CN02808166 A CN 02808166A CN 1306956 C CN1306956 C CN 1306956C
Authority
CN
China
Prior art keywords
gna33
antibodies
strains
antibody
menb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028081668A
Other languages
English (en)
Chinese (zh)
Other versions
CN1602204A (zh
Inventor
D·格拉诺夫
G·莫
R·拉普奥里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccine And Diagnostics Co
Childrens Hospital Oakland Research Institute
Original Assignee
Childrens Hospital Oakland Research Institute
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Oakland Research Institute, Chiron Corp filed Critical Childrens Hospital Oakland Research Institute
Publication of CN1602204A publication Critical patent/CN1602204A/zh
Application granted granted Critical
Publication of CN1306956C publication Critical patent/CN1306956C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028081668A 2001-04-17 2002-04-11 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物 Expired - Fee Related CN1306956C (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28455401P 2001-04-17 2001-04-17
US60/284,554 2001-04-17
US32683801P 2001-10-03 2001-10-03
US60/326,838 2001-10-03
PCT/US2002/011501 WO2002083711A2 (en) 2001-04-17 2002-04-11 Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies

Publications (2)

Publication Number Publication Date
CN1602204A CN1602204A (zh) 2005-03-30
CN1306956C true CN1306956C (zh) 2007-03-28

Family

ID=26962673

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028081668A Expired - Fee Related CN1306956C (zh) 2001-04-17 2002-04-11 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物

Country Status (10)

Country Link
US (1) US7534444B2 (enExample)
EP (1) EP1379272B1 (enExample)
JP (3) JP2004529643A (enExample)
CN (1) CN1306956C (enExample)
AT (1) ATE455793T1 (enExample)
AU (1) AU2002252638A1 (enExample)
CA (1) CA2439428C (enExample)
DE (1) DE60235155D1 (enExample)
RU (1) RU2322451C2 (enExample)
WO (1) WO2002083711A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2457100A (en) * 1999-02-26 2000-09-14 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1179072A2 (en) 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU2000278267A1 (en) 2000-09-01 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae o139 conjugate vaccines
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2005023295A2 (en) * 2003-09-10 2005-03-17 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
CN1918176A (zh) * 2004-02-18 2007-02-21 默克公司 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
DE102004023906A1 (de) * 2004-05-13 2005-12-22 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Verfahren zur Herstellung von chemischen Mikroarrays
SI1961761T1 (sl) 2005-11-30 2010-12-31 Int Inst Cancer Immunology Inc Nove peptidne spojine iz Wilmsovega tumorja
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
DE112009000608B4 (de) 2008-04-18 2017-12-28 Denso Corporation Kälteerzeugungszyklusvorrichtung eines Ejektor-Typs
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
WO2013132040A2 (en) * 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
DE3483957D1 (de) 1983-11-21 1991-02-21 Wellcome Found Komplexe, verfahren zu ihrer herstellung und dieselben enthaltende formulierungen.
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4970070A (en) 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
AU640118B2 (en) 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
US5128460A (en) * 1989-04-04 1992-07-07 Genelabs Incorporated Recombinant trichosanthin and coding sequence
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SU1708846A1 (ru) * 1989-11-22 1992-01-30 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Штамм бактерий NeISSeRIa меNINGIтIDIS серогруппы В - продуцент капсульного полисахарида и полисахаридно-белкового комплекса
RO111416B1 (ro) * 1989-12-14 1996-10-31 Ca Nat Research Council Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare
RU2068270C1 (ru) * 1993-01-13 1996-10-27 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Антиген менингококков группы в
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US6048527A (en) 1996-08-27 2000-04-11 Chiron Corporation Antibodies that define unique Meningococcal B epitopes and vaccine compositions
DE69708318T3 (de) 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
DE69840508D1 (de) 1997-08-27 2009-03-12 Childrens Hosp Medical Center Molekular-mimetika von meningokokkus b epitopen
MX343752B (es) * 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
AU2457100A (en) 1999-02-26 2000-09-14 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
ES2323845T3 (es) * 1999-04-30 2009-07-27 Novartis Vaccines And Diagnostics, Inc. Secuencias genomicas de neisseria y procedimientos de uso.
PT2270030E (pt) * 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Identification of waccine candidates against serogroup Bmening ococus by whole genome sequencing SCIENCE,Vol.287 No.5459 2000 *

Also Published As

Publication number Publication date
US7534444B2 (en) 2009-05-19
US20040013686A1 (en) 2004-01-22
RU2322451C2 (ru) 2008-04-20
AU2002252638A1 (en) 2002-10-28
ATE455793T1 (de) 2010-02-15
DE60235155D1 (de) 2010-03-11
RU2003133300A (ru) 2005-04-20
WO2002083711A3 (en) 2003-11-06
EP1379272B1 (en) 2010-01-20
CA2439428A1 (en) 2002-10-24
EP1379272A4 (en) 2005-12-14
JP2010011868A (ja) 2010-01-21
WO2002083711A2 (en) 2002-10-24
JP2008259503A (ja) 2008-10-30
JP5215275B2 (ja) 2013-06-19
JP2004529643A (ja) 2004-09-30
CA2439428C (en) 2012-01-24
CN1602204A (zh) 2005-03-30
EP1379272A2 (en) 2004-01-14

Similar Documents

Publication Publication Date Title
JP5215275B2 (ja) 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
US6936261B2 (en) Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
Granoff et al. A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis
US20080009022A1 (en) Immunization of dairy cattle with chimeric gapC protein against streptococcus infection
KR20170028442A (ko) 인자 h 결합 단백질 변이체 및 이의 사용 방법
AU2010234193B2 (en) Methods and compositions for treating and preventing Shiga toxin-producing Escherichia coli infection
US6994860B1 (en) Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
WO2003020875A2 (en) Staphylococci surface-exposed immunogenic polypeptides
JP2001514894A (ja) ナイセリア・ラクトフェリン結合プロテイン
US6835384B1 (en) Nucleic acids and polypeptides specific of the neisseria genus pathogenic strains
RU2355704C2 (ru) Моноклональное антитело, направленное против gna33 пептида, и его применение
US8642733B2 (en) T-cell stimulating protein B and methods of use
Neri et al. A Novel Mimetic Antigen Eliciting Protective

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS VACCINES & DIAGNOSTIC; CHILDREN HOSPITAL

Free format text: FORMER NAME OR ADDRESS: CHIRON CORP.; CHILDREN HOSPITAL AUCKLAND INSTITUTE

CP03 Change of name, title or address

Address after: Delaware

Co-patentee after: Children'S Hospital Oakland Research Institute

Patentee after: Novartis vaccine and diagnostics company

Address before: California, USA

Co-patentee before: Children'S Hospital Oakland Research Institute

Patentee before: Hill company

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070328

Termination date: 20140411